This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts Name Top Biotech Stocks for 2010: BioBuzz

"Balance sheet concerns persist with small-cap names although top picks Rigel (RIGL - Get Report), Isis Pharmaceuticals (ISIS), Cardiome (CRME), Array Biopharma (ARRY) and Ariad Pharmaceuticals (ARIA) have benefited from, or should benefit from meaningful partnership funding and support. With M&A as a major theme we continue to advise focus on antibody products, key therapeutics areas like hepatitis C, orphan indications, and companies with shared economics with larger partners."

Biogen Future in Flux as CEO Exits

(At 5:30 AM EST)

Will Carl Icahn be invited to Biogen Idec (BIIB) CEO Jim Mullen's retirement party?

I'm going out on a limb to say probably not. But then this may be the only easily answered question related to Mullen's planned retirement in June and its impact on Biogen's future.

Mullen announced Monday afternoon that he is stepping away from the company, both as CEO and as a director. He gave no specific reason for his departure, although a company spokesman told Dow Jones that Mullen was under no pressure from the board or investors to leave the company.

"Investors" means Icahn, naturally, since the well-known activist hedge fund manager has long taken a keen interest in Biogen. He's also been sharply critical of Mullen's tenure as CEO. Last year, Icahn used his significant ownership stake in Biogen to nominate and seat two directors to Biogen's 11-member board. (Two other Icahn director nominees were not elected.) Prior to that, Icahn pressured Biogen's board to sell the company outright. When a sale didn't happen, he accused Mullen and his management team of sandbagging the process.

When Mullen retires in June, he will have 21 years at the company under his belt. He's been chief executive since 2000, which encompasses CEO stints both before and after the 2003 merger with Idec Pharmaceuticals. Maybe Mullen simply felt it was time to move on.

Or maybe he grew tired of battling with Icahn and was looking ahead with dread to the company's next annual meeting in June when Icahn could once again try to get more of his chosen directors nominated to the board. Interestingly enough, Mullen is up for re-election as a director in June -- a tempting target for Icahn, for sure.
4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ACOR $25.79 1.30%
AMGN $154.23 0.03%
CELG $101.34 0.44%
INCY $69.90 1.80%
RIGL $2.46 -3.00%


Chart of I:DJI
DOW 17,691.94 +40.68 0.23%
S&P 500 2,055.03 +3.91 0.19%
NASDAQ 4,734.1640 +8.5250 0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs